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Abstract: Recent progress in the biochemical classification and structural determination of allergens and allergen–antibody complexes 
has enhanced our understanding of the molecular determinants of allergenicity. Databases of allergens and their epitopes have facilitated 
the clustering of allergens according to their sequences and, more recently, their structures. Groups of similar sequences are identi-
fied for allergenic proteins from diverse sources, and all allergens are classified into a limited number of protein structural families. 
A gallery of experimental structures selected from the protein classes with the largest number of allergens demonstrate the structural 
diversity of the allergen universe. Further comparison of these structures and identification of areas that are different from innocuous 
proteins within the same protein family can be used to identify features specific to known allergens. Experimental and computational 
results related to the determination of IgE binding surfaces and methods to define allergen-specific motifs are highlighted.
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Our current view of allergy as a treatable illness began 
with our ability to first, define and control the allergic 
reaction, and second, to better identify the allergens 
involved. The results of this study, as we will discuss 
in more detail below, have indicated that while aller-
gens do not have one common structure, most of the 
major allergens can be grouped according to common 
features  and,  in  some  cases,  enzymatic    activities. 
Identifying similarities in allergens can be used clini-
cally, to alert patients who are sensitive to substances 
known to trigger extreme allergic reactions, such as 
peanuts, shellfish, or latex, to the presence of similar 
proteins in different sources. Defining characteristic 
features of allergenicity is also needed for regulatory 
purposes, to avoid introducing novel allergenic foods, 
drugs or genetically modified organisms that contain 
proteins similar to known allergens1 and to stipulate 
manufacturing precautions and labeling requirements. 
Future advances in these areas depend on our ability 
to reliably discriminate the properties of allergens that 
distinguish them from structurally related innocuous 
proteins. Here, we discuss some of the physicochem-
ical and structural features of allergens, and motifs 
that can be defined for allergens in the same group 
that differentiate them from non-allergenic structural 
relatives.
not All proteins are Allergenic
Fortunately, only a relatively small fraction of proteins 
in our environment are allergenic. The first efforts to 
define common properties of allergenic proteins in 
the 1970s were limited to characteristics that were 
measureable at that time, such as molecular size, the 
abundance of the protein in airborne sensitizing par-
ticles or, for food allergens, acid or heat stability.2 We 
now  have  gene  and  protein  sequence  information 
for more than 800 characterized allergens. Nuclear 
Magnetic Resonance (NMR) and X-ray crystal three 
dimensional (3D) structures are available in the Pro-
tein Data Bank (PDB)3 for over 60 allergens, includ-
ing such clinically important allergens as birch pollen 
Bet v 1,4 cockroach allergen Bla g 2,5 olive pollen Ole 
e 6,6 maize pollen Zea m 1,7 and cedar pollen Jun a 1.8 
In addition, a large percentage of all allergens with-
out an experimentally determined 3D structure can be 
reliably modelled with current 3D prediction tools.9 
This  increasing  knowledge  of  the    structural  and 
  biochemical properties of allergens makes it   feasible 
to classify allergenic proteins by their 3D structures 
and  to  identify  shared  substructures  that  might  be 
important  for  allergic  sensitization  and  reactions. 
While the idea that a single structural feature common 
to all allergenic proteins responsible for IgE binding 
has yielded to results showing a plethora of different 
structures, we do know that many of the most aller-
genic proteins closely resemble one another and can 
be grouped into discrete families.
Allergen nomenclature and Databases
In response to the large amount of new information 
about  individual  allergens,  the  International  Union 
of  Immunological  Societies  (IUIS)  established  in 
1986  nomenclature  rules  and  criteria  to  evaluate 
the clinical data for substantiating that a protein is 
allergenic,10 which were revised in 1994.11 The list of 
proteins that met these criteria grew rapidly, leading 
to  a  website  (www.allergen.org)  dedicated  to  pro-
teins that are generally recognized as causing allergic 
symptoms in humans. The approved allergens were 
named systematically according to the Latin species 
name of their natural source and the order in which 
they were   identified. By 2001, it was clear that bio-
informatics tools were required to define important 
similarities in the amino acid sequences and struc-
tural  features  of  these  allergens,  since  molecular 
similarities of allergen from different sources are not 
reflected in the nomenclature described above. For 
example, Ara h 1, the first allergen to be identified 
in peanut (Arachis hypogaea), is similar to the vici-
lin allergen Jug r 2, from English walnut (Juglans 
regia), with a sequence identity of 36% and E-value 
of 1.8 × 10–22. The E-values, provided routinely as an 
indication of the extent of sequence similarity identi-
fied by FASTA12 or BLAST searches,13 is a measure 
of how many matches with the same sequence would 
be expected to occur randomly in the database. A very 
low E-value (generally ,0.001) generally indicates a 
highly significant sequence match.
As part of the deregulation process for genetically 
modified (GM) foods, regulatory agencies around the 
world required a more systematic overview of aller-
gen sequences to detect proteins that were potentially 
allergenic based on their sequence similarities. The 
first guidelines were based only on protein sequence 
comparisons. A committee organized by the World 
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Web site and URL Features
IUIS 
International Union of Immunological Societies 
http://www.allergen.org
lists official names 
links to GenBank, UniProt, PDB
SDAP 
Structural Database of Allergenic Proteins 
http://fermi.utmb.edu/SDAP
allergen sequences, structures, Ige epitopes 
links to GenBank, UniProt, PDB 
FASTA search in SDAP 
LAST search in GenBank, SwisProt, PIR 
Pfam classification 
FAO/WHO allergenicity rules 
tools for sequence and epitope comparison 
high-quality allergen models
FARRP 
Food Allergy Research and Resource Program 
http://www.allergenonline.org
allergen list 
FASTA search in FARRP 
FAO/WHO allergenicity rules 
links to GenBank
Allergome  
http://www.allergome.org
allergen list 
links to PubMed, Uniprot, PDB 
links to sequence databases
AllFam 
http://www.meduniwien.ac.at/allergens/allfam
Pfam classification
CSL (Central Science Laboratory, UK) 
http://allergen.csl.gov.uk//index.htm
allergen list 
links to GenBank 
Ige epitopes
InformAll 
http://foodallergens.ifr.ac.uk
clinical data
ADFS (Allergen Database for Food Safety) 
http://allergen.nihs.go.jp/ADFS/
allergen list 
sequences 
Ige epitopes 
3D structures 
epitope search 
FAO/WHO allergenicity rules 
motif-based allergenicity prediction
All Allergy 
http://allallergy.net
allergen list species description
IeDB 
Immune epitope Database and Analysis Resource 
http://immuneepitope.org
T-cell and B-cell epitopes
Allermatch 
http://www.allermatch.org
FAO/WHO allergenicity rules
Health  Organization  (WHO)/Food  and Agriculture 
Organization (FAO) and the European Food Safety 
Authority (EFSA) proposed that a novel protein was 
likely to be an allergen if its amino acid sequence 
was .35% identical to any known allergen, over a 
window of 80 amino acids with a suitable gap pen-
alty, or it contained 6 (or more recently, 8) contiguous 
amino acids that are identical to a known allergen.14–16 
Several  cross-referenced  databases  created  for  the 
comparison of the sequences and properties of aller-
gens (Table 1)17–23 can be used to objectively test the 
utility of these guidelines. While a recent statistical 
analysis  of  the WHO  guidelines  demonstrates  that 
a 35% sequence identity is a realistic cut-off value 
to achieve a good balance between sensitivity and 
specificity,24 the simple identity search for 6 or 8 con-
tiguous residue matches is not a reliable criterion, as 
such analysis provides too many false positives.1,25 In 
one case, cross-reactivity between the Cry1F protein 
and the Der p 7 allergen of dust mite could not be 
confirmed experimentally, even though they share a 
stretch of 6 contiguous amino acids.26
Bioinformatics tools to implement the WHO/FAO 
criteria are widely available, and include the FARRP 
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Database of Allergenic Proteins (SDAP; http://fermi.
utmb.edu/SDAP/)27 and Allermatch (http://allermatch.
org/),28 where a user can rapidly compare molecular 
features of individual or groups of known allergens, 
such as protein sequence, 3D structure, IgE epitopes 
and literature references. Bioinformatics tools incor-
porated in some of these databases allow the user to 
find additional information by cross reference to other 
data bases, such as the protein family of an allergen in 
Pfam,29 the experimentally determined 3D structure in 
the Protein Data Bank,3 gene sequences in GenBank,30 
or publications in PubMed. Bioinformatics analysis 
of the properties of allergens has progressed greatly 
in the last few years, and the established databases 
now  provide  a  solid  scientific  foundation  beyond 
the WHO guidelines for assessing the potential risk 
of  allergenicity  in  GM  foods.24,31 Additional  infor-
mation on B-cell and T-cell epitopes is collected in 
the  Immune  Epitope  Database  (http://www.immu-
neepitope.org/).32 This site also lists peptides from 
the sequences of allergens that have been tested and 
shown not to bind IgE. This information can be useful 
for those designing hypoallergenic proteins designed 
to induce T-cell tolerance.
Classification of Allergens
Grouping allergens into protein families based upon 
their amino acid sequences and biochemical functions, 
as exemplified by the Pfam database,29 has shown that 
there are only a limited number of allergen structural 
classes. The Pfam database is a comprehensive col-
lection of families of proteins with similar biochemi-
cal functions and sequence similarities. As proteins 
are generally composed of one or more domains, each 
domain is separately represented by multiple sequence 
alignments and hidden Markov models (HMMs) and 
annotated with its biochemical function. There are two 
components of Pfam: Pfam-A, a set of high quality, 
manually curated families and Pfam-B, a set of auto-
matically generated domain usually of lower quality. 
Pfam assignments can be obtained from precomputed 
domains using UniProt, TrEMBL or SwissProt acces-
sion numbers, or individual BLAST or HMM profile 
searches of individual allergen sequences.
Two independent studies of the classification of all 
known allergens within two different databases came 
to similar conclusions. All the allergens in the Allfam 
database  (http://www.meduniwien.ac.at/  allergens/ 
allfam) could be grouped into 143 of the 9,318 dis-
tinct  families  in  the  Pfam  database,33  whereas  the 
allergens listed in SDAP database can be grouped into 
130 Pfam families.34 Representative 3D folds of nine 
major protein families that encompass the majority 
of known allergens illustrate the variety of different 
folds of these families (Fig. 1). Members of the same 
protein family in general have very similar 3D protein 
folds, so given a sufficient degree of sequence iden-
tity (above about 35%),35 one can model the structure 
of other family members using the known structures 
as templates. Reliable 3D models, which can be used 
to map experimentally determined linear epitopes and 
predict conformational epitopes, have been prepared 
for most of the allergens in SDAP.9
Molecular and structural Features  
of cross-reactive Allergens
Clinical cross-reactivity is frequently 
observed between allergens from 
different sources
Clinical cross-reactivity between two allergens refers 
to  the  situation  in  which  a  patient  who  has  been 
sensitized to and has IgE antibodies specific for one 
allergen,  also  reacts  to  a  second  allergen.  Patients 
need not have been exposed to the related allergen; 
for  example,  IgE  antibodies  in  sera  of  patients 
sensitized  to Texas  mountain  cedar  also  recognize 
allergens from Japanese red cedar (“Sugi”) pollen.36 
Such cross-sensitivity can be identified from clinical 
history, in vitro quantification of allergen-specific IgE, 
skin test reactivity and provocation challenges with 
purified allergens. Competition assays can be used 
to quantify and verify the findings: preincubation of 
sera with the suspected cross-reactive antigen should 
reduce  the  binding  of  the  IgE  to  the  sensitizing 
antigen.
Some  common  allergen  cross-reactivities  have 
been  explained  by  sequence/structural  similarities 
between proteins from different sources. For example, 
shellfish allergies have been linked to reaction to tro-
pomyosins of more distantly related arthropods, such 
as cockroaches or dust mites, using in vitro and animal 
models.37,38 The cross-reactivity observed for cedar 
pollens across a large array of taxonomically related 
groups,36 can be explained by the fact they all contain 
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pectate lyases and certain pathogenesis-related (PR) 
proteins) that are highly similar in sequence. Similar 
cross-reactivities to plants from different phyla have 
been related to their nearly identical profilins, lipid 
transfer  proteins,  calcium-binding  proteins  and  PR 
proteins.39,40
The  situation  is  more  complex  in  other  impor-
tant food sources, such as nut proteins, where sev-
eral major allergens have been identified. About 35% 
of patients who are allergic to peanuts also react to 
tree nuts, particularly walnuts.41 The major allergenic 
  proteins  in  peanuts  and  walnuts  are  vicilins,  albu-
mins, and pathogenesis related proteins, which have a 
high structural similarity. While the vicilins are quite 
similar, the percent identities of the other allergens lie 
well below the 35% cutoff listed in the WHO rules. 
Sera  from  patients  with  nut  allergies  detect  many 
proteins  and  subsequences  of  known  allergens  on 
Western blots and microarrays, and the patterns dif-
fer greatly from one patient to another.42 Thus, much 
more effort will be required to establish which of the 
ABC
DEF
GHI
Figure 1. Representative experimentally determined X-ray crystal and NMR structures of allergens from the nine most abundant Pfam database   protein 
families. A) Protease inhibitor/seed storage/LTP family (Pfam ID = PF00234); representative allergen LTP from maize (Zea m 14) B) Profilin family 
(PF00235); birch pollen profilin (Bet v 2) c) eF hand (PF00036); pollen allergen from Timothy grass (Phl p 7) D) expansin family (2 domains PF01357 
and PF03330); beta-expansin from maize (Zea m 1) e) Cysteine-rich secretory protein family (PF00188); venom allergen III from fire ant (Sol i 3)   
F) pathogenesis related protein family PR10 (PF00407); cherry allergen (Pru av 1) G) Cupins (PF00190); peanut allergen (Ara h 3) H) lipocalin (PF00061); 
alpha-2U-globulin from mouse (Mus m 1) I) Pectate lyase family (PF00544); major cedar pollen allergen (Jun a 1).
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for cross-reactivity.
In some cases, the source of allergenic triggers do 
not appear to be related to each other; for example, 
in pollen–food allergy syndrome (also known as oral 
allergy  syndrome  (OAS)),  the  sensitizing  allergen 
is often a plant pollen and the trigger is a food pro-
tein. Pollen-food allergy syndrome is elicited by a 
variety of plant proteins cross-reacting with airborne 
  allergens. Symptoms are mostly confined to the oral 
and pharyngeal region after eating foods that have 
not been denatured by cooking. It is estimated that 
OAS affects up to 50%–70% of patients suffering 
from pollen allergy, especially to birch and ragweed. 
These patients were sensitized with pollen allergens 
and symptoms develop when they ingest food which 
contains homologous allergens.
Allergens that can both sensitize and trigger reac-
tions are known as “complete” allergens; those that 
can only trigger reactions in previously sensitized 
individuals  are  known  as  “incomplete”  allergens. 
The latter include Group 2 food allergens, which 
are not sensitizing but cross-react with IgE antibod-
ies that individuals produce in response to aeroal-
lergens, and are implicated in OAS.40 For example, 
some individuals sensitive to the birch pollen aller-
gen Bet v 1 can experience OAS after eating fruits 
of the Rosaceae such as apple, cherries, celery root, 
and carrots, which contain the allergens Mal d l, 
Pru av 1, Api g 1 and Dau c 1, respectively, all of 
which share sequence identity of more than 35% 
with Bet v 1.43–46
Cross-reactive allergens are often  
from the same protein family
The  classification  of  allergens  according  to  Pfam 
also  provides  a  framework  to  explain  clinically 
observed cross-reactivities.27,47–49 For example, simi-
lar lipid transfer proteins (LTP) have been implicated 
in food allergies to cherry (Pru av 3), apricot (Pru 
ar 3), hazelnut (Cor a 8), peach (Pru p 3) and corn 
(Zea m 14). The 3D structures of these proteins form 
a compact four-helix bundle (Fig. 1a) which is stabi-
lized by disulfide bonds. A structural homologue of 
these allergens in plane tree pollen (Pla a 3) may be 
the sensitizing allergen for cross reactivity with pol-
len fruit allergens in the Mediterranean population.50 
Several other studies demonstrated cross-reactivities 
of   structural homologues of LTPs in other foods, such 
as rice, strawberry and cabbage.40
Profilins (Fig. 1b) are pan allergens, considered to 
be  responsible  for  cross-reactivities  between  latex, 
pollen and plant food.51,52 However, not all plant pro-
filins are cross-reactive to the same extent, and ELISA 
inhibition data with sera from different patients could 
be  correlated  in  a  semi-quantitative  analysis  with 
conserved and species-specific epitopes of profilin.53 
The extent of cross-reactivity among profilins from 
Timothy grass, birch, latex and celery was greater 
than  cross-reactivity  to  mugwort  and  bell  pepper 
profilins.
The 3D structures of the cross-reactive allergens 
from grass pollen (Phl p 7), tree pollen (Bet v 4) and 
weed pollen (Che a 3) contain a common domain 
known as the EF-hand, a structural motif for calcium 
binding  (Fig.  1c).54  Other  pollen  allergens,  grass 
allergens Phl p 1 and Phl p 2 from timothy grass 
and  Zea  m  1  from  corn,  are  expansins  that  medi-
ate cell wall extension in plants. Expansins contain 
two domains that form a binding groove for a glycan 
backbone. The first domain, a double-psi beta barrel,55 
resembles the structure of the family-45 glycoside 
hydrolase (GH45), although Zea m 1 lacks a critical 
residue in the active site and does not hydrolyze poly-
saccharides.7 The second domain is an immunoglobu-
lin (Ig)-like β sandwich (Fig. 1d). Common epitopes 
among  corn  and  grass  pollen  allergens  have  been 
located on the protein portion of these expansins, but 
these epitopes of group 1 grass allergens are not con-
served among all members of the expansin superfam-
ily. Five surface exposed regions in the major latex 
allergen Hev b 2 are conserved in the 1,3 β-glucanase 
homologue from banana, and might be responsible 
for latex-banana cross-reactivity.52
These examples illustrate that clinically observed 
cross-reactivities of allergens can often be explained 
by structural similarity of conserved surface patches 
of  allergenic  proteins  in  the  same  protein  family. 
These observations are also valid for other families, 
such  as  the  cysteine-rich  secretory  protein  family; 
PR-10 proteins, cupins, lipocalins, and pectate lyases 
(Fig. 1e–i). Recent annotations of allergen databases 
with protein family relations, such as SDAP or All-
fam  can  alert  physicians  of  allergenic  patients  to 
sources containing structurally related allergens, and 
in  vitro  tests  such  as Western  blotting  and  ELISA 
Schein et al
118  Bioinformatics and Biology Insights 2010:4can then be used to determine whether the patient’s 
serum IgE binds to the allergenic proteins in those 
sources.27,40,48,49,56 New proteomic microarray technol-
ogy allow the detection of IgE-related sensitization 
of large panels of allergens using many sera samples, 
and can provide a comprehensive basis for the rela-
tion between sequence similarity and IgE recognition 
in the future.57
Linear and conformational  
Ige epitopes
Identifying Ige epitope containing  
areas as allergen specific motifs
It  is  possible  that  small  areas  of  similar  sequence 
might  be  sufficient  to  account  for  cross-reactivity 
between sources by constituting an IgE epitope. Two 
different methods have been proposed to define areas 
of sequence and structural homology that are com-
mon  and  distinctive  for  homologous  allergens,34,58 
known as allergen specific motifs (ASMs).
The first approach defines ASMs as MEME motifs 
50 amino acids in length occurring repeatedly in pro-
tein sequences of currently known allergens.59 MEME 
motifs are sequence patterns that are represented as 
probabilities for each amino acid in a position-depen-
dent manner.60 Stadler found that more than 90% of the 
test allergens shared 52 repeating sequence motifs. A 
recent test of the MEME methodology showed that a 
motif-based peptide from tropomyosins had the same 
reactivity with IgE in patient sera as did full-length 
tropomyosins from shrimp.58
The second approach uses the Pfam classification 
of allergens and generates PCPMer motifs, typically 
5–20  residues  in  length.  PCPMer  motifs  are  short 
contiguous  sequences  with  a  statistical  significant 
conservation of physicochemical properties of amino 
acid residues derived from a multiple sequence align-
ment of proteins.61 PCPMer motifs can be generated 
online from any protein sequence alignment with the 
PCPMer suite (http://landau.utmb.edu:8080/pcpmer/
index.jsp); these motifs correspond to some extent 
with known IgE epitopes.34 An algorithm for quan-
titatively assessing the similarity in physicochemi-
cal properties of a sequence amino acids in linear 
epitopes, known as the property distance (PD) scale, 
has been experimentally validated and implemented 
in the SDAP allergen data base.62 The PD scale and 
PCPMer motifs, available on the SDAP web server, 
can be used to screen novel proteins for the presence 
of sequences similar to those found in known aller-
gens to assess the potential risk of allergenicity in 
recombinant food products.24
Defining conformational epitopes
Most of the IgE epitopes that have been elucidated so 
far are “linear” or “continuous” ASMs as they were 
defined by probing overlapping synthetic peptides of 
the allergens for the binding of IgE from the sera of 
allergic patients. However, the epitopes to which IgE 
binds most tightly are most commonly formed by res-
idues that become contiguous on the protein surface 
after folding.5,6,8,63–67 Identifying such “conformational 
epitopes” is currently a major challenge.17,24,27,48,58,68,69 
Experimentally, conformational IgE epitopes can be 
defined most convincingly by examining the crys-
tal structures of complexes of the allergen and the 
binding fragments (Fab) of relevant antibodies.66,70–72 
However,  only  five  X-ray  structures  of  complexes 
of allergen–Fab fragments have been determined so 
far (Fig. 2): the major allergens from Timothy grass 
  pollen  Phl  p  273  and  bovine  milk  β-lactoglobulin 
Bos d 571 with recombinant Fab fragments of human 
IgE; the major allergens from birch pollen Bet v 1,74 
bee venom hyaluronidase Api m 2,72 and the major 
allergen from German cockroach Bla g 2 with mono-
clonal IgG antibodies66 that were shown in competi-
tion assays to bind to or near human IgE epitopes.
Padavattan et al compared the first four of these 
epitopes defined by X-ray crystallography73 and sug-
gested that the flattened shape (formed by four par-
allel β strands) of the Bos d 5 and Phl p 2 epitopes 
recognized by their human IgE antibodies were dif-
ferent from the protruding epitopes of Bet v 1 and 
Api m 2 (formed from a β hairpin and a helix-loop 
helix motif) because these epitopes were recognized 
by IgE vs. IgG antibodies. However, the monoclonal 
IgG antibodies used in the study could be considered 
as surrogates for human IgEs, based on their ability to 
inhibit the binding of human IgG to the target aller-
gen. Subsequently the structure of an epitope of the 
German cockroach allergen Bla g 2,66 a flat area dom-
inated by a quasi-helical structure, was defined in a 
co-crystal with a high affinity IgG monoclonal anti-
body, which effectively competed with patient IgE 
antibodies for Bla g 2 binding. These observations 
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are based on the rather limited data that are currently 
available,  and  additional  co-crystal  structures  are 
needed to define structural patterns of epitopes that 
distinguish epitopes for IgE from IgG responses.
The extent of fragmentation of the sequences that 
form epitopes was also considered as a potential dif-
ference between IgG and IgE epitopes. For example, 
in the IgG epitopes of Bet v 1 and Api m 2, the con-
formational epitopes consist mainly of one contigu-
ous segment of residues. In contrast, the IgE epitopes 
from Bos d 5 and Phl p 2 are formed by four frag-
ments  of  contiguous  residues  and  several  isolated 
residues. The Bla g 2-specific monoclonal antibody 
7C11 binds to the same binding site on Bla g 2 as 
IgE and the epitope consists also of four fragments of 
three or more contiguous residues, with a long frag-
ment of 11 residues.
Another use of crystal structures is to determine 
fine differences that might account for the differ-
ent  reactivities  of  closely  related  proteins.  For 
example, grass pollen allergens were grouped in the 
1960s based on chemical characteristics, including 
molecular  weight  and  isoelectric  point.75,76 There 
is extensive cross-reactivity between group 2 and 
group 3 grass pollen allergens, but none between 
these and the group 1 allergens. An IgE epitope of 
the group 2 Timothy grass pollen allergen Phl p 2 is 
dominated by charged and polar residues that form 
tight contacts (some of them by hydrogen bonds) 
to the antibody (Fig. 3a, b).73 Nine residues within 
hydrogen-bonding  distance  of  IgE  are  conserved 
between  group  2  and  group  3  allergens  (red  in 
Fig. 3c) but are different from the five conserved 
potential  hydrogen-bonding  residues  in  group  1 
allergens (Fig. 3d). We expect that many clinically 
observed cross-reactivities between allergens could 
be  elucidated  based  on  the  structural  features  of 
conformational IgE epitopes.27,40,45,49,54,77
The structural characterization of conformational 
IgE epitopes by X-ray crystal structures is a diffi-
cult and time consuming procedure, since it requires 
monoclonal antibodies that mimic the reactivity of 
human IgE antibodies and production of high quality 
co-crystals. Another approach for defining potential 
conformational epitopes uses random peptide phage 
display  to  identify  mimetic  peptides  (mimotopes). 
Mimotopes are peptides that are generated by phage 
display technology and screened using monoclonal 
antibodies in an iterative selection process.
The selected peptides mimic the binding site of 
the antigen to the chosen antibody and can be lin-
ear or conformational protein, carbohydrates or lipid 
epitopes. In case of carbohydrates and lipids these 
mimetic peptides compete in binding to the chosen 
monoclonal antibody directed against carbohydrate or 
lipid antigen. Both monoclonal IgG78–80 and purified 
IgE81,82 from patient sera have been used with some 
success. Mimotopes can achieve immunogenicity and 
induce epitope-specific antibody responses upon vac-
cination when coupled to suitable carriers. Manual 
or computational methods have been used to locate 
contiguous regions on the surface of the allergen pro-
teins that most similarly match the physicochemical 
structure of the peptide mimetics.36,83 The similarity 
between the phage peptides and areas on the surface 
Api m 2  Bet v 1  Bla g 2  Bos d 5 Phl p 2
Figure 2. Allergens in complex with Ige or IgG Fab fragments. Timothy pollen Phl p 2–Ige; bovine milk beta-lactoglobulin Bos d 5–Ige; German cockroach 
Bla g 2–IgG; birch pollen Bet v 1–IgG; honey bee venom hyaluronidase Api m 2–IgG. Allergens are colored red with epitopes colored yellow, whereas the 
H and L chains of Fab are colored magenta and cyan, respectively.
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using several web servers.83–85
The relation of binding affinities of specific IgE 
epitopes on the physiological effect has been directly 
tested using a panel of recombinant IgE (rIgE) anti-
bodies. For the major dust mite allergen Der p 2 sev-
eral rIgE antibodies with different binding affinities 
were tested for their ability to induce degranulation 
of human blood basophils triggered by different con-
centrations of rDer p 2.86 Their finding strongly sug-
gests that optimal degranulation of basophils requires 
two to three epitope-IgE complexes. Equimolar con-
centrations of the different IgE antibodies were most 
effective; increasing the concentrations of Der p 2 IgE 
antibodies relative to unrelated IgE antibodies was 
important,  and  certain  pairing  of  their  monoclonal 
antibodies to different epitopes was more effective 
than others. This observation might be related to the 
spatial relationships between different IgE epitopes 
on the Der p 2 protein surfaces. Since many allergens 
exist in nature as homodimers, which greatly aug-
ments their ability to activate cells with IgE recep-
tors, the orientation of the dimerization could also 
be an important structural determinant of the relative 
potency of different allergens.
Redesigning Allergenic proteins
The first efforts to reduce allergenicity used chemi-
cal  modification,  for  example  polymerization  with 
aldehyde87  or  coupling  to  methoxypolyethylene.88 
The polymerized proteins diffuse more slowly and 
contain  more  concealed  antigenic  determinants, 
which  are  preferentially  processed  by  phagocytic 
cells (monocytes, macrophages and dendritic cells),87 
are less likely to cross-link IgE antibodies, and more 
likely to be presented to T cells. Proteins coupled 
A
C
B
D
Figure 3. The Phl p 2 Ige epitope and cross-reactivity between grass pollen from group 2 and group 3 but not group 1. A) and B) Phl p 2 Ige epitope 
colored by residue type: hydrophobic and aromatic—green; polar—yellow; positive—blue; negative—red; proline—magenta. C and D: sequence conser-
vation of Phl p 2 epitope residues in multiple alignments with homologs from group 2 and group 3 c) and group 1 D) red—conserved or conservatively 
substituted residues that form hydrogen bonds, yellow—epitope residues that do not form hydrogen bonds.
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T-supressor cells and down regulate the proliferation 
of B cell clones engaged in IgE synthesis.88 Another 
approach is to use fragments of an allergen, obtained 
proteolytically  or  by  recombinant  synthesis;  for 
example, fragments of Bet v 1 cannot bind IgE but 
can activate T cells.89 However, the fragments might 
not fold correctly, thus greatly decreasing their ability 
to generate an IgG response that could reduce subse-
quent IgE sensitization.90 Treatment with fragments 
did not significantly prevent side reactions, such as 
flushing or swelling at the injection site, generalized 
urticaria, pruritus, and even asthma, dyspnoea, circu-
latory dysregulation, and gastrointestinal disturbance 
when compared to the wild type extract.91
The  advent  of  recombinant  allergen  synthesis 
allowed the production of allergen isoforms that are not 
only hypoallergenic, i.e, with reduced IgE binding,92,93 
but that specifically stimulate the production of pro-
tective antibodies (eg, specific IgG, IgA and IgM) 
and regulatory T-cells. For grass pollen allergens, IgE 
epitopes appear different from those that bind other 
allergen classes.94 One can also generate IgG antibod-
ies (IgG1, IgG4 and IgG2 subclasses) to major birch 
pollen allergen Bet v 1 epitopes distinct from those 
recognized by IgE.95–97 There are 10 regions on the 
five allergenic caseins in milk, αS1-casein, αS2-casein, 
β-casein, β-lactoglobulin and κ-casein, that are more 
reactive for IgE than for IgG4.98 At least 44 different 
allergens, mostly aeroallergens, have been modified 
in some way to decrease their allergenicity.99 There 
is also an effort to find ways to modify the immune 
response in individuals with food allergies, or at least 
to label all composite foods to alert those with aller-
gies to possible trace contaminants.
Structural studies can also play an important role 
in the redesigning of proteins to mitigate allergenicity. 
Consistent with the structural observations, patients 
allergic to dust mite produced IgG with binding affin-
ity only to conformational epitopes of the major aller-
gen  Der  p  1,  whereas  IgG  from  non-  symptomatic 
mite-sensitized subjects and normal control individ-
uals bound with similar affinity to both native and 
  pepsin-hydrolyzed Der p 1.100
Other  approaches  use  specific  mutations  of  the 
allergen  that  decrease  their  affinity  for  IgE  while 
retaining the ability to induce T-cell proliferation, as 
successfully demonstrated for Bet v 1.93 Modifying 
T cell epitopes of Cry j 1 yielded a candidate for 
  peptide-based  immunotherapy  of  Japanese  cedar 
pollinosis.101  A  mimotope  gene  of  a  major  IgE 
epitope of Phl p 5, when used to immunize mice, 
did  not  generate  an  IgE  response  and  prevented 
activation of the epitope-specific T cells.102 Another 
interesting recent approach was to couple a hypoal-
lergenic peptide from the major grass pollen allergen 
Phl p 1 to the VP1 surface protein of a human rhino-
virus (HRV). Mice and rabbits immunized with this 
chimeric antigen produced IgG antibodies that recog-
nized group 1 allergens from different grass species, 
blocked allergic patients’ IgE reactivity to Phl p 1, 
and prevented Phl p 1-induced basophil degranula-
tion.103 Further, antibodies were also detected against 
VP1, suggesting that this vaccine might also be useful 
in vaccinating against HRV, which can cause serious 
infections in asthmatics. These successful efforts in 
modifying allergens by mutations and using geneti-
cally engineered allergen derivatives and fusion con-
structs with reduced allergenic activity for specific 
  immunotherapy (SIT) may result in more convenient 
and safer forms of immunotherapy in the near future.
conclusion
Some specific characteristics of allergenic proteins 
have  been  detected  by  combining  experimental 
results with bioinformatics studies. The presence of 
multiple allergens from the same Pfam database fam-
ily in many different plants and animals can explain 
many observed clinical cross-reactivities. However, 
more  structural  information  on  allergen  specific 
motifs and conformational epitopes is needed to make 
reliable in silico predictions about cross-reactivities. 
Fortunately, the progress in producing recombinant 
allergen proteins in sufficient quantities and purity 
for 3D structural analysis by X-ray crystallography 
and NMR techniques have made it possible to obtain 
detailed  structural  information  on  conformational 
IgG and IgE epitopes in several clinically important 
allergens. Thanks to a combination of X-ray, NMR 
and reliable 3D-modelling on a large scale, it is now 
possible to prepare complete maps of conformational 
IgE  epitopes  of  all  major  allergens  based  on  high 
quality 3D experimental structures or models. The 
ability to compare the 3D structures and amino acid 
sequences of allergens with improved bioinformatics 
tools can also provide a rational basis for   regulatory 
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and  for  accepting  novel  recombinant  proteins  as 
food products. Detailed structural data for allergens 
will aid in designing individual proteins for SIT that 
have reduced allergenicity while retaining the ability 
to generate a protective immune response. Progress 
in this area will depend on further definition of the 
common properties of the major families of allergens 
portrayed here.
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